Drug intelligence / Profile preview

XKH009

Development stage: Preclinical
Lead developer: Kanova

Overview

XKH009 is a preclinical drug developed by Zhejiang Xinkanghe Biomedical Technology Co., Ltd. It functions as an inhibitor of both CD276 (B7-H3) and Programmed cell death protein 1 (PD-1), targeting these two immune checkpoints. The drug is currently being investigated for its potential in treating neoplasms, specifically solid tumors, by modulating the immune response.

Targets

PDCD1 (Programmed cell death protein 1 receptor)B7-H3

Beyond the preview

Go deeper on XKH009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XKH009.

Explore the full profile